The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.
 
Eudocia Quant Lee
Honoraria - Medlink
Consulting or Advisory Role - Prime Oncology
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Lorenzo Trippa
Consulting or Advisory Role - Galera Therapeutics
 
Geoffrey Fell
No Relationships to Disclose
 
Rifaquat Rahman
Research Funding - Bristol-Myers Squibb (Inst)
 
Isabel Arrillaga-Romany
Honoraria - Merck
Consulting or Advisory Role - Agios; Boehringer Ingelheim; FORMA Therapeutics; Insys Therapeutics; Karus Therapeutics
Research Funding - Astex Pharmaceuticals
 
Mehdi Touat
Consulting or Advisory Role - Agios; Integragen; Taiho Pharmaceutical
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Jan Drappatz
Leadership - Elsevier
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Pfizer
Honoraria - Agios; Elsevier; Novocure; UpToDate
Consulting or Advisory Role - Agios; Immunomic Therapeutics; Novocure; Oncorus
Patents, Royalties, Other Intellectual Property - uptodate
 
Mary Roberta Welch
Research Funding - Boston Biomedical; Inovio Pharmaceuticals
Travel, Accommodations, Expenses - Boston Biomedical; Inovio Pharmaceuticals
 
Evanthia Galanis
Consulting or Advisory Role - Agios (Inst); Gradalis; Karyopharm Therapeutics (Inst); MedImmune (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); MedImmune (Inst); TRACON Pharma (Inst)
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Abbvie; Apollomics; Bayer; Celularity; Flatiron Health; FORMA Therapeutics; GlaxoSmithKline; InSightec; KIYATEC; Novocure; Nuvation Bio; Tocagen; Varian Medical Systems
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics
 
Louis B. Nabors
Consulting or Advisory Role - BTG; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - Development of novel inhibitors to HuR through NCI funded peer reviewed research.
Other Relationship - University of Pennsylvania; ZIOPHARM Oncology
 
Jaroslaw T. Hepel
No Relationships to Disclose
 
David Schiff
Consulting or Advisory Role - GlaxoSmithKline; Orbus Therapeutics; PRA
Research Funding - Bayer (Inst)
 
David M. Meredith
Consulting or Advisory Role - Blue Earth Diagnostics
 
E. Antonio Chiocca
Stock and Other Ownership Interests - DNAtrix; Immunomic Therapeutics; Seneca Therapeutics
Honoraria - GlaxoSmithKline; Merck
Consulting or Advisory Role - Advantagene; DNAtrix; InSightec; Merck; Sangamo Therapeutics; Voyager Therapeutics
Research Funding - Amgen; Newlink Genetics
Patents, Royalties, Other Intellectual Property - Patents related to oncolytic virus technology, gene therapy, microRNA, exosome, antibodies
 
David A. Reardon
Honoraria - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; DelMar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical
Consulting or Advisory Role - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Omniox
 
Keith L. Ligon
Stock and Other Ownership Interests - Travera
Consulting or Advisory Role - Bristol-Myers Squibb; BroadBranch Consulting; Integragen; RareCyte
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Plexxikon (Inst); Tragara (Inst); X4 Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Molecular Diagnostics Assay Patent
Expert Testimony - Crico
 
Brian Michael Alexander
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Roche
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst)
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)